Last reviewed · How we verify
2014-ALC-919-US
This drug targets the PD-1 receptor to modulate the immune response.
This drug targets the PD-1 receptor to modulate the immune response. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | 2014-ALC-919-US |
|---|---|
| Also known as | ALC-919 |
| Sponsor | Veloce BioPharma LLC |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PD-1 receptor, the drug enhances the body's immune response to cancer cells, allowing for more effective treatment. This mechanism is based on the principle of immune checkpoint inhibition, which has shown promise in various cancer therapies.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
- Arthralgia
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |